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Abstract
A high defibrillation threshold occurs in approximately 6% of implants.  The defibrillation 
threshold can be improved by addition of a defibrillation lead. However, the DF-4 high energy 
ICD header precludes the addition of a defibrillation lead.  Here we report on use of a new 
high voltage adaptor/splitter that enables the addition of an extra defibrillation lead.
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Introduction
In March 2010, the International Organization for Standardization (ISO) formalized a new 
four-pole,  in-line  connecting  system  standard,  the  DF-4  high  energy  lead.  [1,2]  An 
Implantable Cardioverter Defibrillator (ICD) header that complies with the new standard has 
one port that accommodates the coils and the ventricular pace/sense connectors.  This DF-4 
system provides the advantages of easy connection and removal of the lead and smaller header 
size,  while avoiding a mismatch of the high voltage connectors.  A limitation of this new 
standard, however, has been the inability to add ventricular pacing or defibrillation leads to 
the  header.  This  report  describes  the  use  of  a  new,  novel  adaptor/splitter  that  enables 
connecting  a  defibrillating  lead  without  the  need  to  replace  the  ICD  generator.       
Case  report                                           
A  47-year-old  male  with  a  history  of  ischemic  cardiomyopathy  received  an  ICD  for 
spontaneous, hemodynamically unstable sustained Ventricular Flutter (VF). The ICD was a 
Medtronic  Protecta  VR  with  a  quadripolar  DF-4  single  coil  lead  (model  6935M).  The 
maximum shock energy output  for this  generator  is  35 Joules  (J).  Intraoperative  induced 
ventricular  tachycardia  (VT)  at  cycle  length  (CL)  of  300  msec  was  terminated  by  Anti 
Tachycardia Pacing (ATP). A subsequent induced VF was terminated by a 15 J shock on the 
first  attempt.                                                  
A month later, while exercising and after skipping few doses of his heart failure medications, 
the patient sustained five episodes of shocks (Figure 1). Arrhythmia interrogation revealed 
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sustained VT at a CL of 230-240 msec, which was terminated with a 24.8 J shock (Figure 
2A). However, immediately after the initial episode, VT had recurred at a CL similar to first 
episode. A 24.8 J shock was delivered which resulted in a stable VT at a CL of 230 msec and 
what appeared to be a slightly different morphology.  A 35 J shock was delivered (Figure 
2B), which resulted in a stable VT at a CL of 250 msec that was morphologically different 
from previous episodes.  Another shock at 35 J was then delivered, with another change in the 
VT morphology and stabilization of cycle length at 280 msec, which was in the VT therapy 
zone.  In  an attempt  to  terminate  the tachycardia,  ATP was deployed 3 times resulting  in 
acceleration of the VT to a CL of 230 msec (Figure 2C).  Another shock was delivered at 35 
J, which resulted in successful termination of VT after 8 beats with variable CL (Figure 2D).  
Bursts  of  polymorphic  VT  were  noted  after  termination  of  the  VT.  Thus,  2  shocks  at 
maximum output did not terminate the VT, and only the third shock at 35 J resulted in an 
"unclean"  termination  of  the  arrhythmia.  Mexiletine  200 mg twice  daily  was started  and 
patient  was referred to our institution for further management.                            
Figure 1: Arrhythmias and ICD therapies displayed as cycle length over time.
Figure 2A, 2B, 2C, 2D:  Electrocardiograms of arrhythmias and response to therapy. See text.
After careful interrogation,  and failure to identify any reversible causes of the increase in 
defibrillation  thresholds  (complete  metabolic  profile,  cardiac  enzymes),  Mexiletine  was 
discontinued due to concerns that it could further increase the defibrillation threshold. [3] It 
was felt that there was not a sufficient margin of safety in the defibrillation threshold, and 
implantation of subcutaneous shocking lead was planned.                                    
Since  adding  another  lead  is  not  a  possibility  with  the  DF-4  header,  we  arrange  with  a 
manufacturer to get a pre-production adaptor/splitter (Figure 3A) with bifurcated DF-1 and 
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DF-4  inputs  into  the  ICD's  DF-4  header.  A  single-coil  DF-1  subcutaneous  defibrillation 
electrode (Medtronic 6996SQ) was tunneled from the left precordial  area to the left axilla 
(Figure 3B).  The new DF-1 lead and the existing DF-4 lead were both connected to the 
bifurcated  adaptor,  which,  in  turn,  was  connected  to  the  DF-4  port  of  the  original  ICD 
generator.  
Figure 3A: DF-4 adaptor/splitter. Red arrow points to the DF-4 port of the adaptor/splitter to which the RV 
defibrillation  lead  is  connected.  Green  arrow  points  to  the  DF-1  port  of  the  adaptor/splitter  to  which  the 
subcutaneous defibrillation electrode is connected.  Figure 3B: PA view showing subcutaneous defibrillation 
electrode  connected  to  the  adaptor/splitter.                                         
Intraoperative  VF was  successfully  induced  with  shock  on  T.   The  first  shock,  at  15  J, 
successfully  terminated  the  VF  and  sinus  rhythm  emerged.   The  measured  shocking 
impedance was 53 ohms.  A second arrhythmia induction resulted in VT at a CL of 280 msec.  
Five attempts of ATP were deployed with eventual degeneration of the VT into ventricular 
fibrillation.  A 7.9 J shock failed to defibrillate, but a 15 J shock successfully terminated the 
ventricular fibrillation.  A third induction resulted in VT at cycle length of 290 msec, which 
was terminated  with  an  8 J  shock.  ATP was  removed from the  therapies  because  of  its 
ineffectiveness and pro-arrhythmic effects.  Repeat interrogation a month later revealed no 
changes in the defibrillation lead impedance, pacing lead impedance, or pacing thresholds.  
Discussion
The DF-1 standard was designed in early 1990s in order to establish industrial standards and 
uniformity in lead-generator interface. [2]  Depending on the number of defibrillating coils, 
the ICD leads are either bifurcated or trifurcated at the proximal end that fits into the generator 
header.  The major drawbacks of this DF-1 lead system are the bulky ICD header and lead 
yoke, and a concern of possible error in connecting the high voltage pins to the wrong ports in 
the header.  In addition, the multiple set screws of the DF-1 connector create potential for 
problems. The DF-4 standard addresses these shortcomings.  In addition,  the DF-4 header 
offers more reliable long-term sealing by locating sealing rings within the header rather than 
in the lead, as was the case with the DF-1 standard. Thus, new seals are introduced with the 
replacement  of  every  DF-4 generator.                                               
However, the DF-1 header offered several advantages over the new DF-4 standard. The DF-1 
header permitted the addition an extra sense/pace lead using a Y adaptor.  The DF-1 standard 
also enabled an ICD to be downgraded to a pacemaker easily.  Such downgrading may be 
advisable in pacing-dependent  patients,  or CRT responders that  do not  wish to  have ICD 
therapies anymore.  In addition, the DF-1 header allowed the proximal coil pin to be replaced 
with a stand-alone defibrillation lead.  The design of the DF-4 header has so far not offered a 
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solution that enables the addition of a defibrillation lead.                                            
At  times  it  may be  important  to  be able  to  add a  defibrillation  lead  in  order  to  improve 
defibrillation thresholds. High defibrillation thresholds (HDT), defined as <10 J safety margin 
from maximum output, are not uncommon; they are reported in two large studies to be around 
6%  of  ICD  implantations.  [4,5]                                            
 
HDT etiology can be divided into patient-related, device-related, metabolic, medication, and 
procedure-related.  Pre-implantation predictors for HDT are amiodarone therapy, male gender, 
obesity,  left  ventricular  hypertrophy,  and a  wide QRS complex.  [6-9]  Procedure-  related 
factors include loose connections, pocket hematoma, device location, and ICD lead micro-
dislodgement.  Device-related  factors  include  shocking  waveform  morphology,  duration, 
polarity,  and  defibrillation  vectors.  [7]                                          
Some  strategies  have  been  developed  to  reduce  HDT.   In  some  defibrillators,  shocking 
waveform tilt can be modified, which may reduce the defibrillation threshold. [10]  Changing 
the defibrillation vector can result in lowering the defibrillation threshold. The defibrillation 
vector can be changed by repositioning the implanted lead, or adding another defibrillation 
lead.  Some of the options for placement of an added lead are in the azygous vein, in the 
coronary  sinus,  or  subcutaneously.  The  choice  of  such  lead  placement  depends  on  the 
patient's  anatomy and the  operator's  experience.                                       
With  the  DF-1 header  technology,  an  extra  defibrillation  lead  could  be  connected  to  the 
header by a replacing the proximal coil connector in the header, or by connecting both the 
proximal coil and the extra lead with a  Y connector.10 The single port design of the new DF-
4 technology eliminates the possibility of adding an extra coil or lead.  In nearly 0.14% of 
ICD implants, a DF-4 generator has been replaced by an DF-1 system due to an inadequate 
defibrillation safety margin and inability to improve it by adding a lead. [11,12]  The high 
voltage  splitter/adaptor  was  designed  to  address  this  specific  issue.  Here  we  report  a 
successful implantation of a subcutaneous defibrillation lead by using an adaptor/splitter to 
connect to a DF-4 ICD header.  This adaptor/splitter will solve one of the major drawbacks of 
this new technology by enabling the addition of a defibrillation lead.  However, adaptors have 
not yet been developed to address connectivity of a pace/sense lead to a DF-4 system or to use 
an existing DF-4 lead during downgrading of an ICD to a pacing-only system.                 
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